5, 6 or 7 year follow-up control after the SCHEDULE study (SCANDINAVIAN HEART TRANSPLANT EVEROLIMUS DE NOVO STUDY WITH EARLY CNI AVOIDANCE) Title of the original SCHEDULE study: A controlled randomized open-label multicentre study evaluating if early initiation of everolimus (Certican®) and early elimination of cyclosporine (Sandimmun Neoral®) in de novo heart transplant recipients can improve long-term renal function and slow down the progression of chronic allograft vasculopathy. (Protocol: CRAD001ANO02, EudraCT no.: 2009-013074-41)
Latest Information Update: 04 Oct 2019
At a glance
- Drugs Everolimus (Primary) ; Ciclosporin; Corticosteroid; Mycophenolate mofetil
- Indications Heart transplant rejection
- Focus Therapeutic Use
- Sponsors Novartis Norge
- 05 Feb 2018 Status changed from recruiting to completed.
- 01 Feb 2018 This trial has been completed in Sweden (End date: 25 Sep 2017)
- 29 Sep 2016 New trial record